Drug-associated delirium in cancer patients  by Caraceni, Augusto
Drug-associated delirium in cancer patients1359-6349/$ - see front matter Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
http://dx.doi.org/10.1016/j.ejcsup.2013.07.008
* Address: National Cancer Institute, Via venezian 1, 20133 Milano, Italy. Tel.: 39 02 23902792.
E-mail address: Augusto.caraceni@istitutotumori.mi.it.Augusto Caraceni *
Pain Therapy and Rehabilitation, National Cancer Institute of Milan, Italy
European Palliative Care Research Center, Norwegian University of Science and Technology, Trondheim, Norway1. Delirium definition and clinical
characteristics
Delirium is a disorder of consciousness and attention; it is
one of the most common neurological complications seen
in general in the medically ill hospitalised patient, and is also
common in the medical oncology ward [1,2]. Delirium seen in
different settings contributes to defining the diagnoses of di-
verse specificities: postoperative delirium, delirium in the
ICU, withdrawal delirium or delirium tremens, terminal rest-
lessness and others.
Before considering specific clinical contexts or diagnoses it
is necessary to recognise the general characteristics of delir-
ium as a syndrome and its clinical implications. There is
now almost universal agreement on the definition of delir-
ium, or acute confusional state, according to the DSM. How-
ever, acute confusional state is a synonym of delirium and
is still a useful clinical definition, particularly in non-
English-speaking countries. Delirium is a syndrome and not
a disease, and its pathophysiology has not been fully eluci-
dated. Different theories have favoured alternatively the fail-
ure of a common final pathway – mainly regulating the
cholinergic projection to the cerebral cortex – or a more dif-
fused or multifocal impairment of different areas in the
CNS which contribute to maintaining the normal level of vig-
ilance and attention.
Clinically, delirium is an altered state of consciousness
with reduced awareness of self and of the environment,
which may present with inability to think and talk clearly
and rationally; at times there are hallucinations, delusions,
disorientation with respect to time and space, altered sleep–
wakefulness cycle and cognitive impairment. Psychomotor
agitation can be present in the hyperactive deliria, but hypo-
active deliria will show psychomotor retardation and somno-
lence. One extremely important clinical aspect of delirium is
fluctuation of the clinical presentation; symptoms can
change suddenly, often under repetitive conditions (such as
in the classic nocturnal worsening often described in the el-derly with cognitive impairment and called in the past ‘sun-
downing’). These sudden changes from a near-to-normal
mental state to frank delirium often surprise nursing and
medical staff and find them unprepared in front of the patient
and a distressed family.
The clinical presentation of delirium varies, and no de-
fined association of symptoms and signs can be considered
specific [3]. For the purposes of diagnosis and clinical evalua-
tion it is easier to use the DSM criteria as they give a system-
atic approach to the core clinical elements [4]. All four of the
following criteria have to be fulfilled to make a diagnosis.
Disturbance of consciousness (i.e. reduced clarity of
awareness of the environment) with reduced ability to focus,
sustain and shift attention; to fulfil this criterion the levels of
both consciousness and attention need to be affected.
Change in cognition (such as memory deficit, disorienta-
tion and language disturbances) or perception disturbances
that are not better explained by a pre-existing established or
evolving dementia. Testing cognitive function with simple
bedside examinations such as the Minimental test is often
enough to describe disorientation with respect to time and
space, difficulties in performing calculations and in writing
and simple memory tests. In the elderly with previous cogni-
tive failure or being already demented it may be difficult to
distinguish a failure in cognition as part of a chronic condi-
tion from a newly developing delirium (Table 1). Perceptual
disturbances are illusions and hallucinations. Most often
hallucinations are visual, but they are present only in a
percentage of delirious patients and their absence is not a
determinant for the diagnosis [3].
The disturbance develops over a short period of time
(usually hours to days) and tends to fluctuate during the
course of the day. This criterion specifically aims to distin-
guish delirium from chronic conditions, particularly from
dementia (Table 2), but in elderly patients with longstanding
medical complications it may be difficult to differentiate the
contribution of pre-existing neurological factors and inci-
dent acute factors. This distinction may be academic in
Table 1 – Main differential diagnoses of delirium.
Clinical features Delirium Dementia Acute psychosis
Onset Acute Slow Acute
Circadian course Fluctuating Stable Stable
Level of consciousness Affected Spared unless in severe cases Spared
Attention Impaired Initially spared Can be impaired
Cognition Impaired Impaired Can be impaired
Hallucinations Usually visual Often absent Often auditory
Delusions Poorly systematised
and fleeting
Often absent Sustained and
systematised
Psychomotor activity Increased, reduced
mixed with alternating
course
Often normal Can vary, with
bizarre behaviour
depending on the psychosis
Involuntary movements Asterixis, myoclonus
or tremor can be present
in some subtypes
Absent in most forms Absent
EEG Abnormala Abnormala Normal
EEG, electroencephalogram.
*See text for more details.
Table 2 – Frequency of delirium in different patient populations admitted to hospital, hospice or home palliative care
programme.
Population Prevalence (%) at admission Incidence (%) during admission
Elderly P65 admitted to acute hospital unit 10.5 31.3
Elderly P70 admitted to acute hospital unit 25.0
Elderly P70 admitted to acute hospital unit 18.0
Medical oncology unit 18.0
Medical oncology unit 16.5
Hospice 28.0
Hospital palliative care unit 42.0 45.0
Palliative care programme including home care 28.0 –
Dying cancer patients in specialised palliative care unit 80
Modified from Caraceni and Grassi [2].
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many complex cases. Also in the case of advanced cancer
patients, with multiple clinical problems and polypharmacy,
delirium can be a long-lasting complication either character-
ising the final phase of the disease or being a reversible con-
dition [5].
There is evidence from the history, physical examination,
or laboratory findings that the disturbance is caused by the di-
rect physiological consequences of a general medical condi-
tion. This last criterion conceptually distinguishes delirium
from primary psychiatric disease (mainly acute psychosis)
(Table 1). In the old taxonomy this criterion was included in
the construct of organic brain disorder or of recognising an or-
ganic cause of psychiatric symptoms. This terminology is no
longer accepted by the latest DSM versions, but it can be used
to clarify the scope of criterion 4.
Based on the clinical presentation, delirium is distin-
guished into hypoactive, hyperactive and mixed types. The
hyperactive deliria are usually associated with delusions
and hallucination, disruptive or agitated behaviour and often
worsening of symptoms during the night. Hypoactive deliria,
in contrast, show a somnolent detached state of conscious-ness and may be missed or mistaken for depression if the pa-
tient is not assessed more carefully with formal mental task
testing. Mixed hyper- and hypoactive presentations are most
frequent and the transition from hyperactive to hypoactive
delirium, stupor and coma can be seen as one of the ways
of dying.2. Frequency and assessment
The frequency of delirium is high in the acutely hospitalised
patient population, with a prevalence which may be around
10% in the medical ward (excluding the cases of postoperative
delirium). The most relevant patient populations seen by
oncologists are summarised in Table 2, which shows that
the frequency of this complication can not only increase in
more advanced disease, but also that it is common in the el-
derly and as well as in the general oncology ward [6,7].
The diagnosis of delirium should be based on clinical
observation and examination, and can be aided by the sys-
tematic use of screening tools to detect cognitive failure, such
as the Minimental state examination, or tests specifically
Table 3 – Diagnostic and etiological directions in case of delirium in the oncological patient (excluding postoperative
delirium).
Action Assessment
Rule out structural brain lesions Oncological history, neurological examination, brain imaging
if unclear
Rule out seizures, non-convulsive status
epilepticus
When brain lesions are known or suspected EEG may be
necessary
Rule out acute psychotic reactions History of psychiatric disease, young age, psychogenic
unresponsiveness or catatonia
Identify potentially toxic agents Specific (chemotherapy toxicity, brain RT, high-dose
ifosfamide, antivirals, immunosuppressive agents)Consider posterior reversible encephalopathy
(MRI required)
Reduce the risk of drug interactions All generic psychoactive drugs
Any drug can be involved; check metabolic pathways in the
hepatic microsomal oxidising system
Check metabolic factors and vitamin deficiency Renal failure, hepatic failure, electrolyte imbalance, hypoxia,
acidosis, B1 (thiamine) deficit
Think of rarer conditions Paraneoplastic neurological syndromes (usually associated
with unknown or initial neoplastic disease)
EEG, electroencephalogram; MRI, magnetic resonance imaging; RT, radiotherapy.
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Delirium Screening Test (NuDESC). In the validation study by
Gaudreau et al [8], the NuDESC proved sufficiently sensitive to
be used as a screening tool in oncology, although recently a
study on the detection of postoperative delirium in the elderly
showed that sensitivity was too low in this population [9].
Still, a more careful and systematic approach [10] adopted
by the nursing staff is a reasonable strategy and is to be rec-
ommended in oncology and particularly in palliative care set-
tings such as a hospice. The diagnosis finally relies on the
DSM criteria and requires specific expertise. The main differ-
ential diagnoses and their characteristics are listed in Table 1.
3. Diagnostic procedures
As with any new neurological sign or symptom, in a patient
with cancer a change in mental status requires a neurological
examination and, if available, neurological consultation. In
the case of neurological findings suggesting a structural brain
lesion, imaging should be performed. In a patient with cancer,
depending on the stage of the disease, it is not rare for delir-
ium, even without focal neurological signs, to be an initial
presentation of brain or meningeal metastases, as demon-
strated in 15% of patients in one case series [11].
Encephalitis of infectious origin can occur particularly in
immunocompromised patients and occurs not infrequently
after bone-marrow transplantation conditioning
chemotherapy.
Cancer patients are at increased risk of posterior reversible
encephalopathy syndrome (also known as posterior revers-
ible leukoencephalopathy), a syndrome that is probably
caused by damage to the brain vasculature and is found in
association with immunosuppressive therapies (cyclosporine,
tacrolimus), as a complication of transplant, high-dose multi-
drug chemotherapy (cytarabine, cisplatin, gemcitabine, vino-
relbine, FOLFOX regimen and methotrexate) and of the new
biological therapies such as anti-angiogenetic antibodies
and others (bevacizumab, rituximab, bortezomid andmotesa-
nib) [12]. The syndrome usually includes seizures, cortical vi-sual deficit and headache, but at presentation changes in
mental status, or delirium, can dominate the clinical picture.
When seizures are not associated with obvious general-
ised or focal convulsions, the differential diagnosis of delir-
ium can be difficult. In fosfamide encephalopathy
obtundation of consciousness and myoclonus reflect a con-
tinuous seizure-like activity in the electroencephalogram
(EEG).
Patients with a history of psychiatric disorders can develop
acute psychotic reactions, especially when confronted with
serious medical illness such as cancer, with clinical presenta-
tions such as unresponsiveness and catatonia that can be
confused with delirium. These patients are usually young,
and the clinical context helps to exclude the most common
causes or risk factors of delirium.
True paraneoplastic neurological syndromes presenting
with alteredmental state (limbic encephalitis) are indeed very
rare; specific expertise is required for their diagnosis and they
are usually found in association with initial cancer with the
onset of the neurological syndrome preceding the diagnosis
of cancer [13].
Table 3 summarises the elements which can guide clinical
reasoning and a diagnostic strategy when faced with a cancer
patient with delirium that is not occurring after surgery and
general anaesthesia. The clinical context, risk factors, prog-
nosis, associated symptoms and goals of care will influence
the diagnostic path and completeness or futility of any inter-
ventions eventually required.
4. Pathophysiology, risk factors and aetiology
The complex pathophysiology of delirium is beyond the scope
of this chapter [14], but it is important to remember that the
brainstem, thalamic and hypothalamic projections into the
cortex are implicated in the regulation of normal vigilance
and in modulating the level of consciousness between the
physiological states of wakefulness and sleep. This system
has a neurotransmitter organisation, including acetylcholine,
dopamine, serotonin, histamine and c-aminobutyric acid
Table 4 – Factors associated with the risk of developing
delirium resulting from multivariate analysis in cancer.
Modified from Caraceni and Simonetti [17].
Potentially specific predisposing factors:
Advanced age
Previously impaired cognition
History of delirium
Metastatic CNS lesion
Non-specific factors associated with disease progression/
deterioration of general function:
Functional impairment
Severity of illness
Low albumin
Bone metastases
Liver metastases
Haematological malignancies
Potentially specific incident factors:
Metabolic abnormalities
Metastases to brain or meninges
Opioids (dose-related)
Benzodiazepines
Corticosteroids (dose-related)
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thought to have a primary role in delirium pathophysiology.
An impaired cholinergic transmission from the brainstem
and enhanced dopaminergic tone are also thought to play a
causal role in delirium [14]. All drugs with anticholinergic
activity are sedating and can cause delirium. The cholinergic
hypothesis can also explain the increased susceptibility to
delirium of the elderly and of patients with cognitive impair-
ment or dementia, considering that all these situations are
characterised by a reduced function of the cholinergic central
activating system.
Delirium may have many causes, but in most cases a mul-
tifactor model can best explain its pathophysiology, with the
combination of some predisposing conditions and incident
noxious factors. This model was suggested by clinical obser-
vation in early studies on the syndrome [15] and has been
confirmed by well-conducted cohort studies demonstrating
that the combination of specific baseline conditions – such
as advanced age, cognitive impairment, dementia and sever-
ity of illness – was associated with an increased incidence of
delirium when combined with new factors, occurring during
the hospital stay, in elderly patients [16]. Among incident fac-
tors, infections and medications were noted. The results,
summarised in Table 4 [17], can be interpreted by classifying
the associated factors such as structural lesion or functional
abnormalities potentially impairing specific CNS functions
(brain metastases, previous cognitive failure), being direct or
indirect indicators of progression of the disease (metastases),
or of poor general condition and toxic factors (benzodiaze-
pines, opioids and steroids).4.1. The role of drug toxicity
Drug toxicity, in the setting of medical therapy or abuse, is an
extremely frequent cause of delirium (Table 5). The ability to
identify one drug as a cause for delirium depends on anec-
dotal clinical observation, pharmacological knowledge andclinical studies. One recent systematic review of the literature
supports the association of psychoactive medications, con-
sidered together, and use of opioids, which have an indepen-
dent increased risk of developing delirium in cancer patients
[18]. Another review focusing on patients at risk of developing
delirium (elderly patients admitted to hospital for medical
reasons or in the postoperative period) suggests avoiding
the use of benzodiazepines in this population [19].
Experimental human studies demonstrated that anticho-
linergic drugs such as scopolamine, ditran and atropine can
cause delirium depending on dosage [20]. Lower doses usually
produce somnolence (scopolamine 0.3–0.8 mg), higher doses
(atropineP5 mg, scopolamine = 1 mg) agitated florid delirium;
paradoxical effects of low doses have also been demonstrated.
In fact the list of drugs with anticholinergic activity is very
long (Table 6), and such drugs should be used with caution,
especially in the elderly with poor general conditions, multi-
ple medical problems and polypharmacy. Unfortunately all
these conditions are commonly found in cancer patients of
advanced age, with progressive disease and who need appro-
priate palliative therapy for symptom control. Appropriate
selection of drugs with simplified metabolic pathways and
lack of interference would reduce the risk of adverse
reactions.
4.2. Opioids
Opioids are very important drugs for the quality of life of can-
cer patients, and their role in the management of pain and
other symptoms cannot be underestimated. Opioids have
CNS side-effects which include sedation, impairment of cog-
nitive functions [21] and delirium. The central side-effects of
opioids are usually dose-related and can be the main dose-
limiting side-effects in dose titration to obtain better pain
control. High doses of opioids are associated with myoclonus,
delirium, hyperalgesia and eventually seizures [22,23]. Symp-
toms of CNS toxicity can also occur at low doses in individual
cases [24,25]. Recently an independent statistical association
with the use of doses P90 mg of oral morphine per day was
found to be associated with an increased risk of developing
delirium [18]. This means that we have to carefully monitor
the mental status of patients on significant opioid doses
and seek for signs or symptoms of CNS toxicity such as myoc-
lonus and hallucinations. Conversely, the mistake should not
be made of blaming opioids for any complication. Most cases
of delirium will be recognised in complex situations and with
multiple factors together with, if not alternative to, opioid
toxicity alone.
Renal failure can make more difficult the choice of an opi-
oid and increase the risk of delirium due to the accumulation
of toxic metabolites. Drugs which exhibit the safest pharma-
cological profile, when renal failure occurs, are buprenor-
phine, fentanyl, alfentanil, remifentanil and sufentanil [26].
However, simple clinical measures include the choice of an
opioid with least pharmacological interactions (morphine is
the first choice), providing hydration if metabolite accumula-
tion occurs because of reduced renal clearance, reduction of
the dose and substitution of the opioid if toxicity is suspected.
A palliative care consult is helpful to optimise opioid pharma-
cotherapy in these cases.
Table 6 – Drugs with anticholinergic activity in each
category. The agents are listed from the more pronounced to
less pronounced anticholinergic potency.
Prototypical anticholinergics:
Belladonna alkaloids
Atropine
Scopolamine
Hyoscine butylbromide
Robinul
Antidepressants:
Amytriptiline
Imipramine
Desimipramine
Nortriptyiline
Paroxetine
Trazodone
Mirtazapine
Antihistamines:
Marzine
Diphenhydramine
Promethazine
Biperidene
Trihexyphenidyl
Cimetidine
Ranitidine
Neuroleptics:
Chlorpromazine
Flufenazine
Clozapine
Prochlorperazine
Trifluorperazine
Olanzapine
Thioridazine
Haloperidol
Quetiapine
Risperidoone
Ziprasidone
Anti-Parkinsonian:
Amantadine, Levodopa
Other:
Metoclopramide
Baclofen
Entacapone
Table 5 – Case reports of delirium associated with drug
toxicity. Modified from Caraceni and Grassi [2].
Pychotropics:
Clozapine
Diphenydramine
Fluoxetine
Mianserin
Promethazine
Lithium
Risperidone
Antibiotics, antimalarials and antivirals:
Ciprofloxacin
Clarithromycin
Mefloquine
Ofloxacillin
Acyclovir
Gamcyclovir
Drug combinations:
Benzodiazepine/clozapine combination
Flecainamide/paroxetine combination
Diphenhydramine/linezolide combination
Paroxetine/benztropine combination
Lithium/neuroleptic combination
Tacrine/ibuprofen interaction
Ethanol/niacin coingestion
Sertraline/haloperidol/benztropine combination
H-2 receptor blockers:
Famotidine (six cases)
Ranitidine
Ranitidine and cimetidine
Opioids:
Fentanyl
Oxycodone
Morphine
Hydromorphone
Antiblastic:
Paclitaxel
Vincristine
Ifosfamide
Cytosine arabinoside
Cisplatin
Methotrexate
Thiotepa
Etoposide
Nitrosurea
Biological drugs used in cancer:
Bevacizumab
Rituximab
Other:
Diet pills (phentermine)
Amiodarone
Cyclosporin
Donepezil
Herbal medicine loperamide, theales and valerian
Levodopa
Nizatidine
Omeprazole
Paclitaxel
Steroids
Tacrine
Ziconotide
Zolpidem
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The use of steroids is very common in cancer patients. High
doses and prolonged administration can induce delirium, also
called in the past steroid psychosis [27]. Also sudden discon-
tinuation of steroids can cause hypocortisol syndrome and
delirium. It is very important that steroids are given for a lim-
ited amount of time and tapered slowly when no longer nec-
essary. Usually at least a week or two of therapy is needed to
develop psychiatric complications [28]. The symptoms can
range from depression to mania and psychosis. The true inci-
dence of mental changes related to steroid administration in
palliative care is unknown. High doses are often reported to
cause euphoria.
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This significant toxic reaction becamemore frequent with the
spread in the use of serotonin selective inhibitors (SSRIs, e.g.
paroxetine) such as antidepressants. It is usually seen after
the addition of a serotonergic drug to a drug regimen already
containing serotonin-enhancing drugs, and it combines signs
of encephalopathy (confusion, restlessness, myoclonus, hy-
per-reflexia, rigidity and coma) and of autonomic instability
(fever, diaphoresis, diarrhoea, flushing, tachycardia, tachyp-
nea, blood-pressure changes, midriasis, shivering and tre-
mor). It may be fatal or may have a more benign course.
Interactions of different drugs, often used in cancer patients,
should be monitored (SRRI with tramadol, ketobemidone and
venlafaxine). Table 7 lists a number of cases reported in the
literature of drug combinations leading to serotonin syn-
drome. Caution should therefore be exercised not only in
the use of the drugs reported but with all agents with seroto-
nergic action, such as duloxetine and tapentadol, in particularTable 7 – Serotonin syndrome reported in cases of admin-
istration of serotonin reuptake inhibitors alone or in com-
bination with other serotoninergic substances.
Drug Combinations
Fluoxetine Carbamazepine
Pentazocine
MAOIs
Moclobemibe
Nefazodone
Tramadol
Mirtazapine
Fluvoxamine Alone
Nefazodone
Paroxetine Risperidone
Moclobemide
Sertraline Isocarboxazide
Nortriptyline
Tranylcypromine
Erythromycin
Buspirone
Loxapine
Tryptopan Fluoxetine
Non-selective MAOIs
Clomipramine
Venlafaxine Alone
Trazodone Buspirone
Nefazodone
Moclobemide Citalopram
Imipramine
Meperidine Iproniazid
MAOIs
Moclobemide
Phenelzine 3,4-Methylenedioxy-
methamphetamine
Dextrometorphan Non-selective MAOIs
Dothiepine Alone
MOAIs, monoamine oxidase inhibitors.when considering their use in combination with other seroto-
nergic agents.
4.5. Drug pharmacological interactions
The role of metabolic interactions as a cause of toxicity is
more and more likely as the number of drugs increase and
the general patient condition deteriorates. The induction or
inhibition of hepatic enzyme metabolism is an important
source of variability in drug effects and can lead to unex-
pected toxic reactions. The P450 system comprises a family
of more than 20 isoenzymes, among which the CYP 2D6 and
the CYP 3A4 metabolise 80% of known drugs. A relatively re-
cent review [29] reports on a number of examples of drugs
commonly used in oncology and palliative care that have high
or moderate probability of interacting with the same meta-
bolic pathways and of leading to unexpectedly high or low
levels of a drug, with the consequence of under- or over-dos-
ing; examples of such drugs include methadone, codeine,
oxycodone, haloperidol, tricyclic antidepressants (TCAs),
SSRIs, monoamine oxidase (MAO) inhibitors, benzodiaze-
pines, macrolides, azoles, rifampin and antifungals. Table 8
shows a list of interactions that can be particularly relevant
in the management of symptoms in cancer patients.
However, the clinical role of drug interaction in producing
specific effects may be very difficult to ascertain; laboratory
in vitro data may not be applicable to the clinical situation,
while in vivo other circumstances may be operating to change
the effect that was expected on the basis of laboratory data.
For instance, in dogs the co-administration of ketoconazole
and midazolam resulted as expected in a reduced elimination
of midazolam but did not affect the elimination of fentanyl
[30]. Case reports suggest that these interactions are indeed
at times important [31,32].Table 8 – Potential drug interactions with potential elevation
of blood plasma levels of central nervous system active
agents.
CYP2D6 inhibitors Drugs metabolised by CYP2D6
whose plasma levels can
increase when combined with
inhibitors
Cimetidine
Desimipramine
Fluoxetine
Paroxetine
Haloperidol
Sertraline
Oxycodone
Tramadol
Haloperidol
Risperidone
Fluoxetine
Paroxetine
Venlafaxine
Desimipramine
CYP3A4 Inhibitors Drugs metabolised by CYP3A4
whose plasma levels can
increase when combined with
inhibitors
All imidazole
antifungals
Fluoxetine
Norfloxacine
Fentanyl
Alfentanyl
Methadone
Alprazolam
Midazolam
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extremely large and variable according to clinical conditions
and antineoplastic, supportive and combined therapies.
Dexamethasone, anticonvulsants and cisplatin or asparagi-
nase have specific interactions, to give only one example. In
cases of delirium, a specific review of drugs and their metab-
olism is mandatory. Conversely the choice of drugs with the
least metabolic interference potential is to be recommended.
Guidelines to treat pain and depression, for instance, should
recommend as first choice morphine, mirtazapine or citalo-
pram, while TCAs should not be used as first choice in combi-
nation with morphine because of their strong anticholinergic
effects and also because they increase morphine bioavailabil-
ity [33]. However, oral gabapentin has been shown to increase
oral morphine bioavailability [34], but the clinical impact of
this observation has never been clarified.
4.6. Alcohol and drug withdrawal
Patients with known alcohol and or drug abuse, in particular
chronic use of benzodiazepines, should be considered at risk
ofwithdrawalinthecaseofreducedorsuspendedintakeofalco-
hol when admitted to the hospital or hospice. Alcohol with-
drawal delirium should be treated with benzodiazepines; in
severe cases (delirium tremens) this can be life-threatening
and requires specialist advice or intensive care. More subtle
casescanresult fromthesuddendiscontinuationof thechronic
useofbenzodiazepines inpatientswith reducedability to swal-
low when admitted to a care facility, which may go unnoticed
without a very careful assessment of the patient history.
4.7. Delirium as a complication of the terminal phase of
advanced cancer
In patients with advanced cancer undergoing palliative care
and admitted to a hospice, delirium episodes are particularly
frequent; this can be expected from the progressive accumu-
lation of the risk factors described, and indeed the prevalence
of delirium tends to increase as the terminal phase of illness
approaches, reaching 80% in the last days of life, and it is per
se a prognostic factor of shortening life expectancy [7,35]. On
the other hand, in palliative care units and in hospices delir-
ium episodes can be reversible – owing to modifiable etiolo-
gies, such as drugs and infections – in as many as 50% of
the cases [5,36]. It is therefore of extreme importance to as-
sess delirium reversibility in advanced disease, to direct treat-
ment goals and family counselling. When a single drug
toxicity can be identified the probability of reversing toxicity
is also high [36], but on the other hand when the clinical sit-
uation is complex – due to multiple concurrent factors, organ
failure and in an advanced phase of the disease – reversibility
is less likely and delirium can be viewed as one aspect of the
terminal phase of the illness. In this last case, not only can it
be impossible to modify the eventual contribution of drugs to
the delirious state, it could also be futile or even inappropriate
if comfort and quality of dying is the goal of care. Interven-
tions directed at dealing with and managing the impact of
delirium on family distress and anxiety are particularly
appropriate at this time [37].5. Delirium management
Screening of potential etiologies, starting with an accurate
medication list, is the first step in deliriummanagement; con-
sequently a first recommendation is to withdraw all medica-
tions that are not absolutely necessary. Very often finding the
aetiology is delayed, and the time to recovery after modifying
etiological factors can be significant. In a number of cases, as
already discussed above, the multifactor pathophysiology can
be part of a complex clinical picture which does not allow for
recovery or is even part of the dying process. All of these con-
ditions require symptomatic management – in particular to
control hallucinations, delusions and psychomotor agitation
– be it temporary until recovery or continuously until death.
The first-line pharmacological intervention for delirium is
neuroleptics, and haloperidol is the first-choice drug accord-
ing to all clinical guidelines [38–41]. In patients with mild to
moderate delirium, oral medication may be indicated, but
more difficult cases will require parenteral administration.
Haloperidol initial dose can vary from 0.5 to 1 mg, orally or
parenterally b.i.d., according to patient age, and should be ti-
trated in the following hours depending on the severity of
delirium symptoms. Titration of the dose is a fundamental
step before a real lack of clinical response can be docu-
mented, as many treatment failures are failing this recom-
mendation. Parenteral haloperidol can be used via
intramuscular administration. This can be necessary in pa-
tients without an IV line and with very disruptive behaviour,
otherwise an IV infusion can also be adopted. The use of hal-
operidol should be preceded by cardiac monitoring with elec-
trocardiography (ECG), according to some national
regulations, while its intravenous infusion is not officially ap-
proved, although commonly used in different settings of care.
Prolongation of the Q–T interval on the ECG may contraindi-
cate the use of haloperidol. This caveat is based on reports
of cases of fatal cardiac arrhythmia following haloperidol
administration.
Pharmacological treatment of delirium aims at patient
tranquilisation, abolishing hallucinations and delusions,
reducing psychomotor agitation, and improving night-time
sleep. Haloperidol, risperidone or olanzapine, while sharing
a strong tranquilising action, are not primarily sedating
drugs and haloperidol has the least sedating properties
among all the neuroleptics. If required, more sedating neu-
roleptics can be used: for example quetiapine (25–50 mg
b.i.d.), eventually giving a higher dose at bed-time. If this
approach fails, more specific drugs can be added to control
symptoms by keeping the patient sedated, including anti-
histamines, benzodiazepines and eventually alfa-2 agonists
(clonidine, dexmedetomidine). All these regimens require
specialist advice, be it from the neurologist, psychiatrist or
palliative medicine consultant, depending on the clinical
conditions and setting [17].6. Conflict of Interest
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